Thursday's Analysts' Upgrades and Downgrades

Riverbed Technology (RVBD Quote) downgraded at Robert Baird: Robert Baird is downgrading RVBD to Underperform based on competition, lower margins and moderating outperformance. Lowered target price to $25.

Sina (SINA Quote) upgraded at CIBC: SINA was upgraded from Sector Perform to Outperform at CIBC. Company's wireless problems should subside in the first half of the year, and the company remains a key beneficiary of the 2008 Olympics.

Concha y Toro (VCO Quote) downgraded at UBS: VCO downgraded to reduce rating from Neutral at UBS. Price target bumps up slightly to $35.50 from $35.25 and fy 2007 eps estimates remain at $1.31.

STOCK COMMENTS / EPS CHANGES

Affymetrix (AFFX Quote) numbers raised at UBS: AFFX numbers raised at UBS. Price target lifts to $28 from $25 and 2007 eps estimates rise to $0.33 from $0.27. Reiterates Neutral rating.

Cigna (CI Quote)target price raised at Credit Suisse: Credit Suisse is raising its target price on CI to $140 from $125 after 4Q results exceeded estimates. Maintained Neutral rating.

Walt Disney (DIS Quote) target price raised at Credit Suisse: Credit Suisse is raising its target price on DIS to $44 from $41 after Q1 was higher than consensus estimates. Maintained Neutral rating.

Walt Disney price target raised at Goldman: Goldman is increasing its target on DIS to $42 from $41 based on broad-based outperformance and continuing double-digit operating growth beyond 2007. Q1 results showed 45% and 44% growth in operating income and earnings, respectively. Maintained Buy rating.

Electronic Data Systems (EDS Quote) target price raised at Credit Suisse: Credit Suisse is raising its target price on EDS to $31 from $29 following strong Q4 results and inline outlook. Maintained Outperform rating.

Hewlett-Packard (HPQ Quote) estimates increased at Goldman: 2007 estimates on HPQ upped by 2 cents to $2.57 at Goldman. Moving shares back to Conviction Buy list based on expected upside results for January quarter and continuing prospects for expense reduction. Price target raised to $48 from $47.